The United States Patent and Trademark Office (USPTO) has issued patent US12583838B2, titled 'Analogs for the treatment of disease,' to Insilico Medicine Hong Kong Limited. The patent, granted on March 24, 2026, specifically covers kinase inhibitors, including TNIK and/or MAP4K4 inhibitors, with structures defined by Formula (A), (A*), (I), (IIA), or (IIB). It also includes pharmaceutical compositions containing these compounds and methods for their use in treating various diseases.

This patent grant represents a new intellectual property right for Insilico Medicine, potentially impacting the landscape of drug development in areas targeting specific kinases. While patents do not impose direct compliance obligations on other entities, they grant exclusive rights to the patent holder, meaning other pharmaceutical companies or researchers working on similar kinase inhibitors may need to consider licensing agreements or navigate around the patented claims to avoid infringement. The filing date for this application was August 5, 2022, with 12 claims.